Gaia AG   Report issue

For profit Phase 3
Founded: Hamburg Germany (2007)
Status: No NME R&D (2007)

Organization Overview

First Clinical Trial
2019
NCT03937544
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Gaia AG | GAIA Sdn Bhd

Active Ingredients

Drugs in Phase 3 Trials (3)

cd19 car-t cells (1 trial)

cyclophosphamide (cytoxan) (1 trial)

fludarabine (fludara) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3